Annovis Bio, Inc. Common Stock (ANVS)
2.1700
-0.1200 (-5.24%)
NYSE · Last Trade: Jun 26th, 7:00 PM EDT
Detailed Quote
| Previous Close | 2.290 |
|---|---|
| Open | 2.280 |
| Bid | 2.170 |
| Ask | 2.190 |
| Day's Range | 2.100 - 2.401 |
| 52 Week Range | 1.110 - 17.88 |
| Volume | 722,832 |
| Market Cap | 42.29M |
| PE Ratio (TTM) | -1.254 |
| EPS (TTM) | -1.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 643,832 |
Chart
About Annovis Bio, Inc. Common Stock (ANVS)
Annovis Bio Inc is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, particularly conditions like Alzheimer's disease and Parkinson's disease. The company is dedicated to advancing its proprietary platform designed to target and modulate underlying pathologies associated with these diseases. Annovis Bio aims to improve patient outcomes by researching and delivering potential treatments that can enhance cognitive function and overall quality of life for individuals affected by debilitating neurological disorders. Read More
News & Press Releases
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Alzheimer’s Advances at AAIC 2025 in Toronto
Annovis Bio (NYSE: ANVS), a late-stage clinical company focused on therapies for neurodegenerative diseases, announced its leadership will attend the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The company will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap. Topics include the design of a Phase III trial, efficacy and safety data, and comparative pharmacokinetics of different drug formulations in both animals and humans.
Via Investor Brand Network · June 26, 2025
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highlighting advances of Alzheimer’s clinical program and pharmacokinetic characterization of its lead drug candidate, buntanetap.
By Annovis Bio Inc. · Via GlobeNewswire · June 26, 2025
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · June 25, 2025
Via Benzinga · June 25, 2025
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 25, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window
Annovis Bio (NYSE: ANVS), a clinical-stage platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, has received formal acceptance from the New York Stock Exchange of its compliance plan addressing minimum market capitalization and stockholders’ equity requirements. The NYSE granted the company an 18-month window, beginning March 26, 2025, to regain compliance.
Via Investor Brand Network · June 20, 2025
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards relating to minimum market capitalization and stockholders' equity.
By Annovis Bio Inc. · Via GlobeNewswire · June 19, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Webcast With CEO to Share Updates on Alzheimer’s and Parkinson’s Programs
Annovis Bio (NYSE: ANVS) announced it will host a live webcast on June 24, 2025, at 4:30 PM EDT, featuring President and CEO Maria Maccecchini, Ph.D. The event will provide updates on the company’s pivotal Phase 3 trial for early Alzheimer’s disease, recent FDA feedback on its Parkinson’s disease program, and other key initiatives. The webcast will include a brief presentation followed by a live Q&A session open to shareholders, patients, and other stakeholders.
Via Investor Brand Network · June 5, 2025
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience.
By Annovis Bio Inc. · Via GlobeNewswire · June 5, 2025
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 4, 2025
Via Benzinga · May 15, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial and Expands Conference Presence in Q1
Annovis Bio (NYSE: ANVS) initiated its pivotal Phase 3 clinical trial in early Alzheimer’s disease during Q1 2025, with enrollment now underway for up to 760 participants to assess buntanetap’s symptomatic and disease-modifying effects over 18 months. The company also secured a new U.S. patent for buntanetap and participated in several key scientific and investor conferences, including Oppenheimer’s 35th Annual Healthcare Life Sciences Conference and AD/PD(TM) 2025 in Vienna. Cash and equivalents rose to $22.2 million as of March 31, 2025, while R&D expenses fell year-over-year to $5.0 million.
Via Investor Brand Network · May 14, 2025
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results.
By Annovis Bio Inc. · Via GlobeNewswire · May 13, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Appoints Hui Liu as Director of Biostatistics
Annovis Bio (NYSE: ANVS), announced the appointment of Hui Liu as Director of Biostatistics as the company advances its pivotal Phase 3 Alzheimer’s disease trial. Liu brings over 19 years of experience in clinical trial design, analysis and regulatory submission support across multiple therapeutic areas. Annovis stated that Liu’s expertise will help reinforce the scientific integrity of its data and enhance regulatory strategies as it develops transformative therapies for neurodegenerative disorders.
Via Investor Brand Network · April 29, 2025
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment Hui Liu as Director of Biostatistics.
By Annovis Bio Inc. · Via GlobeNewswire · April 29, 2025
Via Benzinga · April 21, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · April 21, 2025
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on therapies for neurodegenerative diseases, disclosed it received a noncompliance notice from the New York Stock Exchange on March 26, 2025, for falling short of continued listing standards under Section 802.01B. The notice stated that the company’s average global market capitalization over a 30-day period was approximately $37.9 million, while its stockholders’ equity as of Dec. 31, 2024, was $9.3 million—both below the $50 million threshold. Annovis will submit a compliance plan within 45 days and may remain listed during an 18-month cure period if the NYSE accepts the plan. Its stock will continue trading under the “ANVS” symbol with a “.BC” indicator reflecting noncompliance status.
Via Investor Brand Network · March 28, 2025
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that on March 26, 2025, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50 million.
By Annovis Bio Inc. · Via GlobeNewswire · March 27, 2025
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, will present key data from its Phase 3 Parkinson’s and Phase 2/3 Alzheimer’s studies at the AD/PD 2025 conference in Vienna from April 1–5. Presentations will highlight buntanetap’s impact on cognition and motor function in early Parkinson’s patients, and its advantages for APOE4 carriers in Alzheimer’s disease. Annovis CEO Maria Maccecchini and SVP Cheng Fang will lead the sessions, with Maccecchini also joining a forum on novel therapeutic and biomarker strategies for PD and related disorders.
Via Investor Brand Network · March 25, 2025
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna.
By Annovis Bio Inc. · Via GlobeNewswire · March 25, 2025
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer’s and Parkinson’s Pipeline, Launches Pivotal Phase 3 Trial
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, reported fourth quarter and full year 2024 results, highlighting major milestones in its buntanetap program for Alzheimer’s and Parkinson’s disease. The company completed two key trials last year, showing cognitive and motor improvements, leading to FDA clearance for a pivotal Phase 3 trial in early Alzheimer’s, which began in early 2025. Annovis also expanded its patent portfolio, strengthened its leadership, and increased investor engagement. Financially, R&D expenses dropped to $20 million for the year, with net loss per share improving to $2.02 basic from $6.23 in 2023. Cash on hand rose to $10.6 million, with additional funding extending runway into Q4 2025.
Via Investor Brand Network · March 24, 2025
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results.
By Annovis Bio Inc. · Via GlobeNewswire · March 21, 2025
The Brain’s ‘Cleanup Crew’ Could Hold the Key to Alzheimer’s Treatment, Study Shows
A new study conducted by a team at Northwestern University suggests that the brain’s immune cells can be enhanced so that they remove amyloid beta plaques more effectively. Amyloid beta plaques are the toxic proteins that form sticky clumps leading to the development of neurodegenerative diseases like Alzheimer’s.
Via Investor Brand Network · March 14, 2025